Why is "Biogen Idec" trending?

Search Interest Perspective

• Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
• Biogen Idec Becomes Biogen - Biogen
• Biogen Idec Provides Business Update at Investor Meeting - Biogen
• Biogen Idec to Present New Two-Year Data from the PLEGRIDY™ (Peginterferon Beta-1a) Phase 3 ADVANCE Study at AAN Annual Meeting - Biogen
• Biogen Idec Names Hans Peter Hasler Chief Operating Officer - Biogen
• Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion - Biogen
• FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
• Biogen Idec Reports First Quarter 2011 Results - Biogen
• Biogen Idec Announces President and Chief Executive Officer James C. Mullen to Retire - Biogen
• Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer - Biogen
• Biogen Idec Completes Purchase of Full Rights and Control of TYSABRI® - Biogen
• Biogen Idec Appoints Eric Rowinsky and Stephen Sherwin to Board of Directors Pursuant to Agreement with Icahn Partners - Biogen
• Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS - Biogen
• FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart - Biogen
• Biogen Idec Announces Conclusion of Arbitration with Genentech - Biogen
• Biogen Idec 2013 Total Revenues Increase 26 Percent to $6.9 Billion - Biogen
• Biogen Idec and Genentech Announce Restructuring of anti-CD20 Collaboration Agreement - Biogen
• Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global Collaboration to Develop Gene Therapies for Hemophilia - Biogen
• Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter - Biogen
• Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy - Biogen
• Biogen Idec Receives Conditional Approval in the European Union for FAMPYRA® to Improve Walking in Adults with Multiple Sclerosis - Biogen
• Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter 2013 - Biogen
• Biogen Idec Opens New RTP Facility - Biogen
• Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference - Biogen
• Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology - Biogen
• Biogen Idec Names Caroline Dorsa to Board of Directors - Biogen
• Biogen Idec and Elan Enroll First Patient in Large, Well-Controlled Head-to-Head Study of Multiple Sclerosis Treatments - Biogen
• Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders - Biogen
• Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases - Biogen
• Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities - Biogen
• Biogen Idec Names Brian S. Posner to Board of Directors - Biogen
• Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals - Biogen
• Biogen Idec and Knopp Neurosciences Announce License Agreement for Late-Stage ALS Drug Candidate - Biogen
• Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development - Biogen
• Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis - Biogen
• Biogen Idec 2014 Revenues Increase 40% to $9.7 Billion - Biogen
• Biogen Idec Submits Application to FDA for First Long-Lasting Factor VIII Therapy for Hemophilia A - Biogen
• Biogen Idec and Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX® Pediatric Study - Biogen
• Biogen Idec Receives Negative Opinion from the CHMP on FAMPYRA - Biogen
• Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub - Biogen
• Biogen Idec and PDL BioPharma License the Rights to Develop Volociximab in Ophthalmic Indications to Ophthotech - Biogen
• Biogen Idec Fully Acquires Biogen Dompé Joint Ventures - Biogen
• Biogen Idec Announces Framework for Growth Through Increased Focus and Efficiency - Biogen
• Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia - Biogen
• Biogen Idec and Sobi to Donate 1 Billion International Units of Clotting Factor to Support Treatment of Hemophilia in Developing World - Biogen
• Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) - Biogen
• Biogen Idec Announces Enrollment of First Patient in Phase II BG-12 Combination Trial in Multiple Sclerosis - Biogen
• Biogen Idec Adds Senior Leadership to Commercial and Medical Operations - Biogen
• Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals - Biogen
• Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in anti-JCV Antibody Negative Patients with MS - Biogen
• Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A - Biogen
• FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children - Biogen
• Biogen Idec Announces Collaboration with Leading Research Institutions to Sequence Genomes of Patients with ALS - Biogen
• Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S. - Biogen
• Biogen Idec Sells BENLYSTA Royalty Rights to DRI Capital Managed Fund - Biogen
• Biogen Idec and Sobi Present New Data from the Phase 3 Study of Their Long-Lasting Hemophilia Factor Candidate ELOCTATE - Biogen
• Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis - Biogen
• Biogen Idec Names Michael Lytton Executive Vice President of Business Development - Biogen
• Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research - Columbia University Irving Medical Center
• Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for Upfront Cash and Contingent Payments - Biogen
• Biogen Idec Announces Appointment of Nancy L. Leaming to Board of Directors - Biogen
• Biogen Idec to Acquire Stromedix - Biogen
• Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis - Biogen
• Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS) - Biogen
• Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS - Biogen
• Biogen Idec Celebrates 30 Years of Transforming Discovery into Care - Biogen
• Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer - Biogen
• Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis - Biogen
• Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus - Biogen
• Phase IIb Data Published in the Lancet Show That BG-12, Biogen Idec's Novel Oral Compound, Significantly Reduced Brain Lesions in Patients with Multiple Sclerosis - Biogen
• Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapsing-Remitting Multiple Sclerosis - Biogen
• Roche and Biogen Idec Announce Their Decision to Discontinue the ocrelizumab Clinical Development Programme in Patients with Rheumatoid Arthritis - Biogen
• Biogen Idec rebrands as Biogen, bets big on neurodegenerative pipeline - BioPharma Dive
• Preliminary Data in Support of Investigational Anti-JCV Antibody Assay Published in the Annals of Neurology - Biogen
• Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies - PR Newswire
• CHMP Determines Dimethyl Fumarate in TECFIDERA® to be a New Active Substance in the European Union - Biogen
• Promising Multiple Sclerosis Research Partnership Between Biogen Idec, Regulus Renewed - Multiple Sclerosis News Today
• Researchers Report Neublastin Virtually Restores Complete Long-Term Sensory Motor Function in Preclinical Studies - Biogen
• Biogen Idec's Study Reviews Positive Results Over Five Years of Tecfidera RRMS Treatment - Multiple Sclerosis News Today
• New TYSABRI® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity - Biogen
• New Analysis of Risk Stratification for TYSABRI® Published in New England Journal of Medicine - Biogen
• Biogen Idec Pharmaceutical Production Facility - Pharmaceutical Technology
• Biogen Idec’s Injection Plegridy Approved in Europe to Treat RRMS - Multiple Sclerosis News Today
• Biogen Idec appoints senior neuroscientists - PMLiVE
• FDA News Roundup: Biogen Idec, GSK, Roche, And More - Clinical Leader
• Biogen Idec, University of Edinburgh Team Up for Neurodegenerative Disease R&D - Genetic Engineering and Biotechnology News
• Adriana Karaboutis joins Biogen Idec from Dell - PMLiVE
• First Ten-Year Follow-Up Shows That Treatment with AVONEX® Leads to Long-Term Benefits in Early Multiple Sclerosis Patients - Biogen
• Biogen Idec and Genentech Tweak Anti-CD20 Alliance to Prevent Future Squabbles - Genetic Engineering and Biotechnology News
• Changes in Kendall make cafeteria rule for Biogen Idec unnecessary, officials argue - Cambridge Day
• Biogen Idec and Facet—Following the Money - Genetic Engineering and Biotechnology News
• GEN’s 30th Anniversary: Biogen Idec - Genetic Engineering and Biotechnology News
• Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack) - PR Newswire
• New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US - Biogen
• Biogen Idec, Elan file Tysabri for first-line use - PMLiVE
• Unilabs to Offer Companion Diagnostic Services for Biogen Idec’s Tysabri - Genetic Engineering and Biotechnology News
• CHMP backs oral MS drugs from Sanofi, Biogen Idec - PMLiVE
• Biogen Idec Changes Name to Biogen - Contract Pharma
• Biogen Idec Gives $1.4M to New MS Research Program in Alberta - Multiple Sclerosis News Today
• Biogen Idec Restructuring will Close Sites and Divest Oncology Assets to Save $300M a Year - Genetic Engineering and Biotechnology News